Early evaluation and value-based pricing of regenerative medicine technologies

Regenerative Medicine

Volumn 8, Issue 6, 2013, Pages 747-758

  Koerber, Florian ^a   Rolauffs, Bernd ^b,c   Rogowski, Wolf ^a,d  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

business planning; commercialization; early evaluation; innovation management; market access; pricing; reimbursement

Indexed keywords

COCODAMOL;

ARTICLE; CHONDROCYTE IMPLANTATION; COLLAGEN MATRIX COVER AUTOLOGOUS CHONDROCYTE IMPLANTATION; COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FIBROCARTILAGE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HYALINE CARTILAGE; KNEE ARTHROPLASTY; KNEE ARTHROSCOPY; KNEE OSTEOARTHRITIS; MARKETING; MATRIX ASSOCIATED AUTOLOGOUS CHONDROCYTE IMPLANTATION; MICROFRACTURE; MOSAICPLASTY; PERIOSTAL FLAP COVER AUTOLOGOUS CHONDROCYTE IMPLANTATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REGENERATIVE MEDICINE; REOPERATION; TREATMENT FAILURE; VALUE BASED PRICING;

CARTILAGE; COSTS AND COST ANALYSIS; GROSS DOMESTIC PRODUCT; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; REGENERATIVE MEDICINE;

EID: 84886515692     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.13.69     Document Type: Article

References (36)

1. Mason C. Regenerative medicine. The industry comes of age. Med. Device Technol. 18(2), 25-30 (2007
2. Prescott C. The business of exploiting induced pluripotent stem cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366(1575), 2323-2328 (2011
3. Mason C, Dunnill P. The strong financial case for regenerative medicine and the regen industry. Regen. Med. 3(3), 351-363 (2008
4. Prescott C. Regenerative nanomedicines: An emerging investment prospective? J. R. Soc. Interface 7(Suppl. 6), S783-787 (2010
5. Rogowski WH, Hartz SC, John JH. Clearing up the hazy road from bench to bedside: A framework for integrating the fourth hurdle into translational medicine. BMC Health Serv. Res. 8(194), 1-12 (2008
6. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3(8), 711-716 (2004
7. Claxton K, Briggs A, Buxton MJ et al. Value based pricing for NHS drugs: An opportunity not to be missed? BMJ 336(7638), 251-254 (2008
8. McKernan R, McNeish J, Smith D. Pharmas developing interest in stem cells. Cell Stem Cell 6(6), 517-520 (2010
9. Briggs A, Claxton K, Sculpher M. Decision Modelling For Health Economic Evaluation. Oxford University Press, UK (2006
10. Dimasi JA, Caglarcan E, Wood-Armany M. Emerging role of pharmacoeconomics in the research and development decision-making process. Pharmacoeconomics 19(7), 753-766 (2001
11. Annemans L, Geneste B, Jolain B. Early modelling for assessing health and economic outcomes of drug therapy. Value Health 3(6), 427-434 (2000
12. Hartz S, John J. Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical review. Int. J. Technol. Assess. Health Care 24(4), 465-472 (2008
13. Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur. J. Health Econ. 11(2), 195-203 (2010
14. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: The pharmaceutical industrys grand challenge. Nat. Rev. Drug Discov. 9(3), 203-214 (2010
15. Mason C, Manzotti E. The translation cycle: Round and round in cycles is the only way forward for regenerative medicine. Regen. Med. 5(2), 153-155 (2010
16. Gregson N, Sparrowhawk K, Mauskopf J, Paul J. Pricing medicines: Theory and practice, challenges and opportunities. Nat. Rev. Drug Discov. 4(2), 121-130 (2005
17. Claxton K. OFT, VBP: QED? Health Econ. 16(6), 545-558 (2007
18. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS Evidence based medicine: What it is and what it isnt. BMJ 312(7023), 71-72 (1996
19. EuroQol-A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16(3), 199-208 (1990
20. Trueman P, Grainger DL, Downs KE. Coverage with evidence development: Applications and issues. Int. J. Technol. Assess. Health Care 26(1), 79-85 (2010
21. Drummond MF. Methods For the Economic Evaluation of Health Care Programmes (2nd Edition). Oxford University Press, UK (1997
22. Weinstein MC, OBrien B, Hornberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices-modeling studies. Value Health 6(1), 9-17 (2003
23. Jette N, Quan H, Hemmelgarn B et al. The development, evolution, and modifications of ICD-10: Challenges to the international comparability of morbidity data. Med. Care 48(12), 1105-1110 (2010
24. Backhouse ME, Wonder M, Hornby E, Kilburg A, Drummond M, Mayer FK. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: A pilot study. Value Health 14(4), 608-615 (2011
25. Stafinski T, McCabe CJ, Menon D. Funding the unfundable: Mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 28(7), 608-608 (2010
26. Willis M, Persson U, Zoellner Y, Gradl B. Reducing uncertainty in value-based pricing using evidence development agreements: The case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopå) in Sweden. Appl. Health Econ. Health Policy 8(6), 377-386 (2010
27. Vasiliadis H, Wasiak J, Salanti G. Autologous chondrocyte implantation for the treatment of cartilage lesions of the knee: A systematic review of randomized studies. Knee Surg. Sports Traumatol. Arthrosc. 18(12), 1645-1655 (2010
28. Hughes DA. Value-based pricing incentive for innovation or zero net benefit? Pharmacoeconomics 29(9), 731-735 (2011
29. Gerlier L, Lamotte M, Wille M et al. The cost utility of autologous chondrocytes implantation using ChondroCelect(R) in symptomatic knee cartilage lesions in Belgium. Pharmacoeconomics 28(12), 1129-1146 (2010
30. Henderson I, Lavigne P, Valenzuela H, Oakes B. Autologous chondrocyte implantation: Superior biologic properties of hyaline cartilage repairs. Clin. Orthop. Relat. Res. 455, 253-261 (2007
31. Losina E, Walensky RP, Kessler CL et al. Cost-effectiveness of total knee arthroplasty in the United States: Patient risk and hospital volume. Arch. Intern. Med. 169(12), 1113-1121; discussion 1121-1112 (2009
32. Knutsen G, Engebretsen L, Ludvigsen TC et al. Autologous chondrocyte implantation compared with microfracture in the knee. A randomized trial. J. Bone Joint Surg. Am. 86-A(3), 455-464 (2004
33. Knutsen G, Drogset JO, Engebretsen L et al. A randomized trial comparing autologous chondrocyte implantation with microfracture. Findings at five years. J. Bone Joint Surg. Am. 89(10), 2105-2112 (2007
34. Bentley G, Biant LC, Carrington RW et al. A prospective, randomised comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects in the knee. J. Bone Joint Surg. Br. 85(2), 223-230 (2003
35. Marcacci M, Kon E, Delcogliano M, Filardo G, Busacca M, Zaffagnini S. Arthroscopic autologous osteochondral grafting for cartilage defects of the knee: Prospective study results at a minimum 7-year follow-up. Am. J. Sports Med. 35(12), 2014-2021 (2007
36. Bartlett W, Skinner JA, Gooding CR et al.: Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee: A prospective, randomised study. J. Bone Joint Surg. Br. 87(5), 640-645 (2005